Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
2.000
+0.160 (8.70%)
At close: Dec 20, 2024, 4:00 PM
1.950
-0.050 (-2.50%)
After-hours: Dec 20, 2024, 5:51 PM EST
Immuneering Stock Forecast
IMRX's stock price has decreased by -74.29% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Immuneering stock have an average target of 12.8, with a low estimate of 3.00 and a high estimate of 25. The average target predicts an increase of 540.00% from the current stock price of 2.00.
Analyst Consensus: Buy
* Price targets were last updated on Nov 20, 2024.
Analyst Ratings
The average analyst rating for Immuneering stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 4 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +550.00% | Nov 20, 2024 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +650.00% | Nov 14, 2024 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +650.00% | Sep 13, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $16 → $12 | Strong Buy | Maintains | $16 → $12 | +500.00% | Aug 7, 2024 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +650.00% | Aug 7, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.93
from -1.88
EPS Next Year
-1.71
from -1.93
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | |||
| Avg | n/a | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.74 | -0.97 | -1.28 | |||
| Avg | -1.93 | -1.71 | -2.09 | |||
| Low | -2.04 | -2.31 | -2.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.